ArrowMark Colorado Holdings LLC Acquires New Holdings in Stevanato Group S.p.A. (NYSE:STVN)

ArrowMark Colorado Holdings LLC purchased a new stake in Stevanato Group S.p.A. (NYSE:STVN - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 243,788 shares of the company's stock, valued at approximately $5,312,000. ArrowMark Colorado Holdings LLC owned 0.08% of Stevanato Group as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Van Berkom & Associates Inc. bought a new position in Stevanato Group in the 4th quarter worth approximately $39,000. Johnson Financial Group Inc. bought a new stake in shares of Stevanato Group during the fourth quarter valued at about $41,000. Wells Fargo & Company MN grew its position in Stevanato Group by 680.3% in the 4th quarter. Wells Fargo & Company MN now owns 3,246 shares of the company's stock valued at $71,000 after buying an additional 2,830 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Stevanato Group by 1,457.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company's stock valued at $123,000 after buying an additional 5,291 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in shares of Stevanato Group by 202.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,413 shares of the company's stock worth $162,000 after buying an additional 4,965 shares in the last quarter.

Analysts Set New Price Targets

STVN has been the subject of several research reports. William Blair reaffirmed an "outperform" rating on shares of Stevanato Group in a research note on Friday, March 7th. Stephens upgraded Stevanato Group to a "strong-buy" rating in a research report on Monday, April 21st. Finally, UBS Group reduced their price objective on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research note on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Stevanato Group has an average rating of "Moderate Buy" and a consensus price target of €25.70 ($29.20).

Stevanato Group Trading Down 4.0 %

Stevanato Group stock traded down €0.89 ($1.01) during midday trading on Tuesday, hitting €21.24 ($24.14). 655,600 shares of the stock were exchanged, compared to its average volume of 346,813. Stevanato Group S.p.A. has a 52 week low of €16.56 ($18.82) and a 52 week high of €28.08 ($31.91). The stock has a market capitalization of $6.43 billion, a PE ratio of 45.19, a P/E/G ratio of 7.18 and a beta of 0.51. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The company has a fifty day simple moving average of €20.87 and a two-hundred day simple moving average of €20.90.

Stevanato Group (NYSE:STVN - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.23) EPS for the quarter, meeting analysts' consensus estimates of €0.20 ($0.23). The company had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Equities research analysts anticipate that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Stevanato Group Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, July 17th. Shareholders of record on Thursday, June 5th will be given a dividend of $0.0613 per share. The ex-dividend date is Thursday, June 5th. This is an increase from Stevanato Group's previous annual dividend of $0.05. This represents a yield of 0.3%. Stevanato Group's dividend payout ratio (DPR) is 12.50%.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.